Research reportPeripheral DISC1 protein levels as a trait marker for schizophrenia and modulating effects of nicotine

- Detection of a protein from a major mental illness gene, Disrupted-in-Schizophrenia 1 (DISC1) in lymphocytes of humans.
- Demonstration of decreased levels of lymphocytic DISC1 in patients with schizophrenia suggesting its potential for a schizophrenia biomarker.
- Demonstration that peripheral DISC1 levels are modulated by nicotine but not to the degree of interfering with schizophrenia diagnosis establishing its possible peripheral readout for psychotropic drug effects.
- Demonstration that administration of nicotine leads to decreased aggregated DISC1 in the rat mPFC.

The Disrupted-in-Schizophrenia 1 (DISC1) protein plays a key role in behavioral control and vulnerability for mental illnesses, including schizophrenia. In this study we asked whether peripheral DISC1 protein levels in lymphocytes of patients diagnosed with schizophrenia can serve as a trait marker for the disease. Since a prominent comorbidity of schizophrenia patients is nicotine abuse or addiction, we also examined modulation of lymphocyte DISC1 protein levels in smokers, as well as the relationship between nicotine and DISC1 solubility status. We show decreased DISC1 levels in patients diagnosed with schizophrenia independent of smoking, indicating its potential use as a trait marker of this disease. In addition, lymphocytic DISC1 protein levels were decreased in smoking, mentally healthy individuals but not to the degree of overriding the trait level. Since DISC1 protein has been reported to exist in different solubility states in the brain, we also investigated DISC1 protein solubility in brains of rats treated with nicotine. Sub-chronic treatment with progressively increasing doses of nicotine from 0.25 mg/kg to 1 mg/kg for 15 days led to a decrease of insoluble DISC1 in the medial prefrontal cortex. Our results demonstrate that DISC1 protein levels in human lymphocytes are correlated with the diagnosis of schizophrenia independent of smoking and thus present a potential biomarker. Reduced DISC1 protein levels in lymphocytes of healthy individuals exposed to nicotine suggest that peripheral DISC1 could have potential for monitoring the effects of psychoactive substances.